Date: 2012-06-06
Type of information: Development agreement
Compound: biosimilar compounds in oncoloy (mainly monoclonal antibodies)
Company: Merck KGaA, Merck Serono (Germany) Dr Reddy's (India)
Therapeutic area: Cancer - Oncology
Type agreement: co-development
production
manufacturing
commercialisation
Action mechanism:
Disease: cancers
Details: Merck KGaA and Dr Reddy\'s laboratories have concluded a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.
Dr Reddy\'s will lead early product development and complete phase I development. Upon completion of phase I, the Merck Serono division will take over manufacturing of the compounds and will lead phase III development. Merck Serono will undertake commercialization globally, outside the US and with the exception of select emerging markets which will be co-exclusive or where Dr Reddy\'s maintains exclusive rights.
Financial terms: The agreement is based on full R&D costs sharing. At the time of commercialization, Dr Reddy\'s will receive royalty payments from Merck Serono. In the US, the parties will commercialize the product on a profit-sharing basis. Additional terms of the deal were not disclosed.
Latest news:
